Abstract

Nuclear mutations are well known to drive tumor incidence, aggression and response to therapy. By contrast, the frequency and roles of mutations in the maternally inherited mitochondrial genome are poorly understood. Here we sequence the mitochondrial genomes of 384 localized prostate cancer patients, and identify a median of one mitochondrial single-nucleotide variant (mtSNV) per patient. Some of these mtSNVs occur in recurrent mutational hotspots and associate with aggressive disease. Younger patients have fewer mtSNVs than those who diagnosed at an older age. We demonstrate strong links between mitochondrial and nuclear mutational profiles, with co-occurrence between specific mutations. For example, certain control region mtSNVs co-occur with gain of the MYC oncogene, and these mutations are jointly associated with patient survival. These data demonstrate frequent mitochondrial mutation in prostate cancer, and suggest interplay between nuclear and mitochondrial mutational profiles in prostate cancer.

Details

Title
Mitochondrial mutations drive prostate cancer aggression
Author
Hopkins, Julia F 1 ; Sabelnykova, Veronica Y 1 ; Weischenfeldt, Joachim 2 ; Simon, Ronald 3 ; Aguiar, Jennifer A 1 ; Alkallas, Rached 1 ; Heisler, Lawrence E 1 ; Zhang, Junyan 4 ; Watson, John D 1 ; Chua, Melvin L K 4   VIAFID ORCID Logo  ; Fraser, Michael 4 ; Favero, Francesco 5 ; Lawerenz, Chris 6 ; Plass, Christoph 7 ; Sauter, Guido 3 ; McPherson, John D 8   VIAFID ORCID Logo  ; Theodorus van der Kwast 9 ; Korbel, Jan 10   VIAFID ORCID Logo  ; Schlomm, Thorsten 11 ; Bristow, Robert G 12 ; Boutros, Paul C 13   VIAFID ORCID Logo 

 Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada 
 Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany; Biotech Research & Innovation Centre (BRIC) and Finsen Laboratory, Copenhagen, Denmark 
 Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 
 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada 
 Biotech Research & Innovation Centre (BRIC) and Finsen Laboratory, Copenhagen, Denmark 
 Division of Theoretical Bioinformatics, German Cancer Research Center, Heidelberg, Germany 
 Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany 
 Genome Technologies Program, Ontario Institute for Cancer Research, Toronto, ON, Canada 
 Department of Pathology and Laboratory Medicine, Toronto General Hospital/University Health Network, Toronto, ON, Canada 
10  Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany 
11  Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany 
12  Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada 
13  Informatics and Biocomputing Program, Ontario Institute for Cancer Research, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada 
Pages
1-8
Publication year
2017
Publication date
Sep 2017
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1953963949
Copyright
© 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.